Savara Inc Research and Development in Process
Savara Inc (SVRA) reported Research and Development in Process of $5.37 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-03-30
- Savara Inc research and development in process for the quarter ending 2020-12-31 was $0.00.
- Savara Inc research and development in process for the quarter ending 2020-09-30 was $0.00.
- Savara Inc research and development in process for the quarter ending 2020-06-30 was $0.00.
- Savara Inc research and development in process for the quarter ending 2020-03-31 was $5.37M.
- Savara Inc research and development in process for fiscal 2020 was $5.37M.
- Savara Inc research and development in process for fiscal 2006 was $10.40M.
| Period end | Research and Development in Process | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month | Research and Development in Process 181 month | Research and Development in Process 184 month | Research and Development in Process 187 month | Research and Development in Process 190 month | Research and Development in Process 193 month | Research and Development in Process 196 month | Research and Development in Process 199 month | Research and Development in Process 202 month | Research and Development in Process 205 month | Research and Development in Process 208 month | Research and Development in Process 211 month | Research and Development in Process 214 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $0.00 derived: sum of 3 quarters · filed 2022-03-30 | $5.37M 10-K · filed 2022-03-30 | |||||||||||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $5.37M 10-Q · filed 2021-11-12 | ||||||||||||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $5.37M 10-Q · filed 2021-08-12 | |||||||||||||||
| 2020-03-31 | $5.37M 10-Q · filed 2021-05-13 | ||||||||||||||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $995.00K 10-Q · filed 2019-11-07 | |||||||||||||||
| 2018-06-30 | $995.00K 10-Q · filed 2019-08-08 | ||||||||||||||||
| 2015-09-30 | $0.00 10-K · filed 2016-03-14 | ||||||||||||||||
| 2014-09-30 | $0.00 10-K · filed 2015-03-24 | ||||||||||||||||
| 2014-03-31 | $10.42M 10-Q · filed 2014-05-05 | ||||||||||||||||
| 2013-12-31 | $10.42M 10-K · filed 2014-03-26 | ||||||||||||||||
| 2013-09-30 | $10.42M 10-Q · filed 2013-11-04 | ||||||||||||||||
| 2013-06-30 | $10.42M 10-Q · filed 2013-08-05 | ||||||||||||||||
| 2013-03-31 | $10.42M 10-Q · filed 2013-05-15 | ||||||||||||||||
| 2012-12-31 | $10.42M 10-K · filed 2013-03-19 | ||||||||||||||||
| 2012-09-30 | $10.42M 10-Q · filed 2012-11-05 | ||||||||||||||||
| 2012-06-30 | $10.42M 10-Q · filed 2012-08-06 | ||||||||||||||||
| 2012-03-31 | $10.42M 10-Q · filed 2012-05-07 | ||||||||||||||||
| 2011-12-31 | $10.42M 10-K · filed 2012-03-08 | ||||||||||||||||
| 2011-09-30 | $10.42M 10-Q · filed 2011-11-08 | ||||||||||||||||
| 2011-06-30 | $10.42M 10-Q · filed 2011-08-08 | ||||||||||||||||
| 2006-12-31 | $10.40M 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |